|
Drug Licenses: A New Model For Pharmaceutical Pricing
Dana P. Goldman,
Anupam B. Jena,
Tomas Philipson and
Eric Sun
High drug prices are a major barrier to patients’ access to drugs and compliance with treatment. Yet low drug prices are often argued to provide inadequate incentives for innovation. We propose a drug-licensing model for health care, which has the promise of increasing drug use without altering patients’ out-of-pocket spending, health plans’ costs, or drug companies’ profits. In such a model, people would purchase annual drug licenses that would guarantee unfettered access to a clinically optimal number of prescriptions over the course of a year. Using the example of statins, we illustrate how such a model could be implemented.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
M. R. Nuwer, G. J. Esper, P. D. Donofrio, J. P. Szaflarski, G. L. Barkley, and T. R. Swift
Invited Article: The US health care system: Part 1: Our current system
Neurology,
December 2, 2008;
71(23):
1907 - 1913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
